Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP015K dose-finding study in methotrexate-inadequate responder rheumatoid arthritis
2011-006018-15Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peficitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Astellas Pharma. Primary endpoint: ACR20 response rate at Week 12. Started Jul 2012; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006018-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006018-15.